See questions answered by Suzanne Hendrix As researchers push into the frontier of early-stage and preventative Alzheimer's disease clinical trials, they will have to measure whether a drug works in people who do not have dementia yet. Traditional ou
Upcoming WebinarsNo Upcoming Webinars Available
26 July 2011 Listen to the Webinar Background Text by Gabrielle Strobel ApoE reigns supreme
2006 Apr 19;26(16):4277-88. Abstract Bayer TA, Schäfer S, Breyhan H, Wirths O, Treiber C, Multhaup G.
On 19 April 2011, the National Institute on Aging (NIA) and the Alzheimer’s Association (AA) published new guidelines for the diagnosis of Alzheimer’s disease (AD) and its pre-dementia and preclinical phases (see ARF related news story on McKhann et al.,
When two biological networks as complex as the nervous and immune systems cross paths, you know the interaction is not going to be simple. Add in neurodegeneration—such as amyotrophic lateral sclerosis—and it creates a web that will take many scientists t
Alois Alzheimer made a major breakthrough when he discovered senile plaques in the brains of dementia patients, and his work ultimately led to the discovery of amyloid-β and to the amyloid cascade hypothesis. But that cascade is only part of a much bigger
the study found that only 2.6 percent of patients, most of them young, reported mild post-LP headache,
In this Webinar, Clifford Jack gave a slide talk summarizing a staged biomarker model of the Alzheimer’s cascade, followed by a panel discussion with Chet Mathis, David Holtzman, Henrik Zetterberg, Paul Aisen, Keith Johnson, Giovanni Frisoni, Douglas Gala
in mice: Cross-seeding as a disease mechanism. Proc Natl Acad Sci U S A. 2005 Apr 26
On 26 February 2009, we held a Webinar/Live Discussion with a slide presentation by Scott Small
Alzheimer's disease: a dual pathway hypothesis. Neuron. 2008 Nov 26;60(4):534-42. Abstract 0 Thursday, March
that these patients in fact have AD and not some other form of dementia? Reply by Douglas Galasko — Posted 26 July
Sports Concussions, Dementia, and APOE Genotyping: What Can Scientists Tell the Public? What’s Up for Research?
This live discussion was held on 26 June 2008 with Sam Gandy, Mount Sinai School of Medicine, New
and thereby prevent TNFα transcription (25,26). A possible post-translational therapeutic target in AD is TACE
Peter T. Nelson led this Webinar from 12:00-1:30 p.m. (U.S. Eastern Time) on Friday, 26
Have a topic idea for a webinar? We would love to hear it. Send an email to webinars [at] alzforum [dot] org.